Narazaciclib not checked
Hangzhou Hanx Biopharmaceuticals, Ltd. · HX301 · HX301 Monolactate Capsules
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total
What this is
- How it works
- Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
- How it’s given
- “Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional "3 + 3" rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not…”In the company’s words, NCT06703255 on ClinicalTrials.gov
- Tested for
- Glioma
- Main trialPhase 1/2
- “The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes.”In the company’s words, NCT06703255 on ClinicalTrials.gov
- Other names
- HX301 · HX301 Monolactate Capsules · ON123300 · ON 123300 · HX-301
Other drugs for Glioma
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- DordaviproneJazz Pharmaceuticals · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
Coming up1
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 31 Dec 2026 | A Phase 2 Study of HX301 in Patients with High-grade Giloma | |
| Phase 1/2Unknown | Jan 2026 | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | |
| Phase 1Completed | 12 Jan 2024 | The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors | |
| Phase 1Unknown | Oct 2024 | Study of ON 123300 in Patients With Advanced Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026